Breast Cancer
Conditions
Brief summary
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Detailed description
This is a single-arm, open-label study designed to evaluate the efficacy and safety of NBQ72S in patients with breast cancer leptomeningeal metastasis (with or without brain parenchymal metastasis). Patients will undergo screening prior to study entry. After screening successfully, they will receive intravenous infusion of NBQ72S. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of informed consent, or any other conditions except as specified in the protocol (whichever occurs first). However, patients who demonstrate clinical benefits (despite radiological progression) with manageable toxicity, and are willing to continue receiving the NBQ72S, will be given the opportunity to continue treatment after the assessment and confirmation of Investigator. After treatment completion, patients will undergo safety follow-up and long-term survival follow-up until death or lost to follow-up.
Interventions
DRUGNBQ72S
Patients will receive the study drug every 28 days
Sponsors
Nantong Bencao Quadriga Medical Technology Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have histological evidence confirming the diagnosis of breast cancer with leptomeningeal metastasis: a. Breast cancer must be diagnosed through biopsy from either the primary or metastatic sites; b. Leptomeningeal metastasis (with or without brain parenchymal metastases) must be confirmed by imaging examinations(MRI), or by positive or suspicious cerebrospinal fluid cytology; c. There is no restriction on the duration of prior systemic therapy for the primary tumor. * The patient's Karnofsky Performance Status (KPS) must be ≥60. * The patient must have adequate bone marrow function, including: 1. Absolute neutrophil count (ANC) ≥1,500/mm³ or ≥1.5 x 10⁹/L; 2. Platelet count ≥100,000/mm³ or ≥100 x 10⁹/L; 3. Hemoglobin ≥9 g/dL; * The patient must have adequate renal function, including: a. Serum creatinine ≤1.5 x upper limit of normal (ULN) or estimated creatinine clearance ≥50 mL/min. Note: In equivocal cases, a 24-hour urine collection test can be used to estimate the creatinine clearance more accurately; * The patient must have adequate hepatic function, including: 1. Total serum bilirubin ≤1.5 x ULN; if the tumor involves the liver, or if the patient has a history of Gilbert's syndrome, total bilirubin must be \<3 x ULN; 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN; if the tumor involves the liver, these values must be ≤5.0 x ULN; * Females of childbearing potential and males with fertile partners must agree to use effective contraception during the study and for 7 months following the last dose of study treatment;
Exclusion criteria
* Patients with any other active malignancies unrelated to the primary tumor, except for those with basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma that have been adequately treated. * Patients who are intolerant to any substance in the investigational product, including sulfobutylether-β-cyclodextrin, mefenamic acid, bendamustine, chloramphenicol, or any nitrogen mustard chemotherapy agents, or who have experienced a severe (Grade ≥3) allergic or hypersensitivity reaction to these substances. * Patients who have received a live vaccine or experimental drug within 30 days prior to Cycle 1, Day 1 (C1D1). * Pregnant or breastfeeding patients. * Any other conditions that may affect the patient's eligibility for this study in the judgment of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | through study completion, an average of 1.5 years | Overall Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracrarnial PFS | through study completion, an average of 1.5 years | Intracrarnial Progression Free Survival |
| Intracrarnial DOR | through study completion, an average of 1.5 years | Intracrarnial Duration of Response |
| Extracrarnial ORR | through study completion, an average of 1.5 years | Extracrarnial Objective Response Rate |
| Extracrarnial PFS | through study completion, an average of 1.5 years | Extracrarnial Progression Free Survival |
| Extracrarnial DOR | through study completion, an average of 1.5 years | Extracrarnial Duration of Response |
Countries
China
Contacts
CONTACTRaylene Liu
PRINCIPAL_INVESTIGATORBinghe Xu
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed